Counterfeit Peptide Supply Chain Risks

The grey-market peptide supply chain has predictable failure modes. This page lists them — not to help readers navigate the supply chain, but to explain why we treat vendor claims with skepticism.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Common counterfeit patterns

• Underfilled vials — labelled mg amounts that do not match net weight.
• Substitute compounds — a vial labelled as one peptide actually containing another, or none at all.
• Photocopied COAs — a single COA reused across unrelated batches.
• Edited HPLC traces — graphical edits to mask impurity peaks.
• Fake third-party labs — “third-party tested” that does not name an identifiable accredited laboratory.
• Relabelling — expired or unsold inventory relabelled and resold.

Why this is structurally hard to detect

White powder looks like white powder. Even a careful researcher cannot, by eye, confirm peptide identity, concentration, or contamination profile. Genuine third-party testing requires sending samples to an accredited laboratory and paying for an HPLC and/or mass-spectrometry assay per batch — a cost most end-users will not bear.

Vendor claims are not evidence

On PeptideStacks we do not treat marketing claims, product pages, or vendor statements as evidence. Our content is anchored to the published literature and to regulatory documents. See: citation standards.

What this site does not do

We do not list reputable vendors, rank suppliers, or provide sourcing guidance. The supply-chain problem is real — we describe it — but the appropriate response is not to choose a “better” grey-market vendor.